Aims-To assess the value of immunophenotyping of acute lymphoblastic leukaemia (ALL) in routinely processed bone marrow trephine biopsy specimens and to establish a minimum panel of antibodies to assess lymphoid lineage and enable differentiation from acute myeloid leukaemia. Methods-45 routinely processed bone marrow biopsy specimens (formalin fixed, paraYn embedded and mildly de- 1999;52:688-692) 
Immunophenotyping has yielded significant new information on the heterogeneity of acute lymphoblastic leukaemia (ALL) and has provided a solid basis for a reproducible classification system. 1 The classification of ALL is performed by a combination of cytomorphological, enzyme-cytochemical, and immunocytological techniques. Although the immunohistochemical examination of routinely processed bone marrow biopsy specimens has become an essential part of diagnostic haematopathology, acute leukaemia (unlike malignant lymphoma) [2] [3] [4] [5] [6] has been the subject of relatively few immunohistochemical studies. 1 7-10 In most of these studies, a relatively small panel of antibodies was applied or only small numbers of cases were examined. The recent development of antibodies directed against important stem cell and B cell associated antigens (for example, TdT and CD10) 11 12 that can be used on routinely processed tissue has enabled us to study the value of immunophenotyping of ALL in routinely processed bone marrow biopsy specimens and to establish a panel of antibodies to assess lymphoblastic lineage and exclude the diagnosis of acute myeloid leukaemia.
Methods
Forty five bone marrow biopsy specimens from patients diagnosed as having ALL on the basis of cytomorphological, enzyme-cytochemical, and immunocytological investigation of blood and bone marrow smears were drawn from the archives of the Institute of Pathology, University of Tübingen, Germany. The diagnoses were common ALL (c-ALL) (22) , T cell ALL (T-ALL) (11), B cell ALL (B-ALL) (2) and ALL not further classified (u-ALL) (10) .
All specimens had been processed routinely by fixation in 5% neutral buVered formalin, mild decalcification in edetic acid (EDTA) for 12 hours, 13 14 and embedding in paraYn. Serial sections were cut at 4 µm and stained with haematoxylin and eosin (H&E), Giemsa (fig 1) , the periodic acid-SchiV reaction (PAS), and the naphthol AS-D chloroacetate esterase reaction (CAE).
Immunostaining was performed by the avidin-biotin-peroxidase complex (ABC) method of Hsu et al, 15 using the 26 antibodies listed in table 1. The number of immunoreactive cells was recorded on a four grade scale: 0, none; +, up to 10% of nucleated bone marrow cells; ++, 10-50% of blast cells; +++, more than 50% (usually 100%) of blast cells (figs 2-4). When only a few of the nucleated bone marrow cells were immunoreactive (less than 10%) it was usually impossible to determine whether these were non-neoplastic lymphoreticular cells (histiocytes or T cells) or neoplastic blast cells. Grade "+" was therefore not included in the analysis as "positive" immunostaining. Fisher's exact test, grouping together grades "0" and "+" and grades "++" and "+++," was used for statistical analysis. Probability values of less than 0.05 were considered significant.
Results

GENERAL CONSIDERATIONS
In routinely stained sections (H&E, PAS, Giemsa), the bone marrow in almost all cases was found to be extremely hypercellular, with subtotal depletion of fat cells and normal blood cell precursors. Sheets of small to medium sized blast cells with slightly pleomorphic, round to ovoid nuclei, scanty cytoplasm, and only occasional prominent nucleoli dominated the histological picture in most cases. CAE positive blast cells were detected in three cases, in which the diagnosis subsequently proved to be acute myeloid leukaemia (AML-M4 (2); AML-M1 (1)) rather than ALL.
IMMUNOHISTOCHEMICAL FINDINGS
A summary of the immunohistochemical findings is given in tables 2-4. Staining with antibodies against myeloperoxidase (MPO) and lysozyme showed that seven of the 45 cases were biphenotypic or mixed leukaemias (2), or showed clear myeloid diVerentiation: AML-M1 (2); AML-M4 (2), AML-M5a (1). Three of the specimens in which compact leukaemic infiltrates could not be detected were excluded from further analysis, leaving 35 ALL cases for evaluation.
Nineteen of the 26 antibodies reacted with more than 10% of the blast cells in at least one case (table 2) . The blast cells in each case reacted with at least three and at most 11 of the antibodies applied, and they tended to react with more antibodies in c-ALL than in T-ALL or B-ALL (tables 3 and 4). Twenty three of the cases were classified as c-ALL, eight as T-ALL and two as B-ALL; two could not be classified definitively (u-ALL). By definition, the blast cells of c-ALL showed immunoreactivity for CD10. Most cases of c-ALL also expressed CD43, CD99, CD45RB, TdT, CD79a, and CD34 (tables 3 and 4). The main diagnostic marker was F1 in six of the cases of T-ALL. The blast cells in the two cases of B-ALL expressed the B cell associated antigens CD79a and CD20. The blast cells of four of the seven initially unclassified cases (u-ALL) showed strong immunoreactivity for CD10, thus allowing a diagnosis of c-ALL to be made. In one case, F1 expression led to a diagnosis of T-ALL. The remaining two cases had an inconclusive immunophenotype that did not allow definitive subtyping (table 4) . In summary, the original diagnosis of ALL was confirmed in 38 of the 45 cases (> 80%), and it was possible to subtype five of the seven initially unclassified cases of u-ALL.
STATISTICAL FINDINGS
Statistical analysis of the immunohistochemical findings showed that antibodies against the stem cell associated antigens TdT and CD34 reacted more often with the blast cells of ALL than with those of AML (p < 0.05). CD10 was found to be expressed more often in c-ALL than in T-or B-ALL (p < 0.05).
Discussion
The main findings of the study were as follows. (1) In most cases the subtyping of ALL into c-ALL and T-ALL can be performed using routinely processed bone marrow trephines if an appropriate panel of antibodies, comprising anti-CD10, anti-CD79a, anti-CD20, and F1, is applied. (2) ALL can be diVerentiated from AML by the application of antibodies against TdT, MPO, and lysozyme.
Currently employed systems for the classification of acute leukaemias are based mainly on cytomorphological, enzyme-cytochemical and immunocytological findings in blood and bone marrow smears. When bone marrow aspiration is unsuccessful, the clinician has to rely on a paraYn embedded bone marrow trephine biopsy specimen for diagnosis. The value of antibodies that can be used on routinely processed tissue for the subtyping of acute leukaemia has been assessed in various studies. 1 7-10 Chuang and Li 10 suggested a panel of antibodies against MPO, CD79a, CD20, and CD3 for CD43  20  7  2  2  CD99  19  8  0  2  CD45RB  17  4  2  1  TdT  18  5  0  1  CD79a  13  0  2  0  CD34  11  0  0  1  CD21  9  3  0  0  CD20  6  0  2  1  bcl-2  7  2  0  0  F 1  4  6  0  0  MB1/CD45RA  2  1  0  1  CD45R  2  1  0  0  LN3  2  0  0  0  CD45R0  2 the immunohistochemical typing of most cases of acute leukaemia. Our study, unlike others, included only cases that had been diagnosed as ALL on the basis of blood and bone marrow smears. In addition, we were also able to apply a broader panel of antibodies against haemopoietic antigens, including CD10 and TdT, as more antibodies for use on paraYn embedded tissue have recently become available.
Our findings are generally consistent with those of other studies performed on routinely processed bone marrow biopsy specimens containing infiltrates of ALL, in that it was also found that lymphoid blast cells show marked heterogeneity. 1 7-10 Like Chuang and Li, we found that antibodies against MPO, CD79a, and CD20 are very useful for the classification of acute leukaemia. However, in contrast to studies in which anti-CD3 proved to be the most sensitive T cell marker, 9 10 we found F1 to be the most reliable and sensitive antibody for the diagnosis of T-ALL.
By using antibodies against MPO and lysozyme, we showed that seven of the cases originally diagnosed as ALL were in fact biphenotypic or mixed acute leukaemias, or showed clear signs of myeloid or myelomonocytic diVerentiation. MPO and lysozyme are highly specific markers for myeloblasts and monoblasts, respectively. 5 16 The haemopoietic stem cell associated antigen CD34 is expressed by lymphoid and myeloid progenitor cells and blast cells of both ALL and AML. 17 18 The antibody anti-CD34 cannot therefore be used to determine the cell lineage, but may be useful for the diVerentiation of acute leukaemia from high grade non-Hodgkin lymphoma. 1 19 However, TdT is regarded as a highly sensitive marker of immature lymphoid cells, its localisation producing a nuclear staining pattern. An antibody against TdT has been developed for use on routinely processed bone marrow biopsy specimens. 6 Of the 35 cases of ALL in our study, 13 expressed CD34 and 25 expressed TdT.
We tested a broad panel of antibodies suitable for use on routinely processed tissue to determine their value in the subtyping of ALL, and found the antibodies anti-CD10, antiCD79a, anti-CD20, and F1 to be of great diagnostic value. All of the 23 cases of c-ALL in our study showed immunoreactivity with a newly developed antibody that detects CD10 in paraYn sections. Immunoreactivity for CD10 was also detected in four of the seven initially unclassified cases, which could then be reclassified as c-ALL. CD79a and CD20 are both specific B cell antigens that are expressed on normal, reactive, and neoplastic B cells. [20] [21] [22] [23] [24] [25] Both the cases of B-ALL but none of the cases of T-ALL were found to express these antigens. c-ALL  1  CD10, CD20, CD21, MB1/CD45RA, MT2/CD45RA, CD45RB, CD43, bcl-2, CD45R0  2  CD10, CD20, CD21, MB1/CD45RA, CD45RB, CD43, F1  3  CD10, CD45RB, CD43, CD99  4  CD10, CD21, CD34, TdT, CD43, CD99  5  CD10, CD79a, CD21, CD34, TdT, CD43, CD99  6  CD10, CD79a, CD21, TdT, CD43, F1, CD99, bcl-2  7  CD10, CD45RB, CD34, TdT, CD43, CD99, F1  8 CD10, CD79a, CD45RB, CD34, TdT, CD43, CD99, bcl-2 9 CD10, CD20, CD21, LN3, CD34, TdT, CD43, CD99 10 CD10, CD79a, CD45RB, TdT, CD43, CD3, OPD4, CD99 Of the eight T cell antibodies applied, F1 proved to be the most sensitive for the diagnosis of T-ALL, staining six of the eight cases. The other T cell specific antibodies, such as anti-CD3 and F1, were found to be much less sensitive, anti-CD3 staining only two cases and F1 none.
CONCLUSIONS
In summary, we conclude that the subtyping of ALL is usually possible in routinely processed bone marrow trephine biopsy specimens, and we suggest a panel of antibodies against TdT, CD34, MPO, lysozyme, CD10, CD79a, and CD20, and the antibody F1 as a minimum for subtyping acute leukaemia. However, the combined evaluation of both bone marrow biopsy specimens and blood and bone marrow smears by enzyme-cytochemical and immunocytological techniques still appears to represent the best approach for the rapid subtyping of cases of acute leukaemia.
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